Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
UCART-123 by Cellectis for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
UCART-123 is under clinical development by Cellectis and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
UCART-123 by Cellectis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
UCART-123 is under clinical development by Cellectis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
UCART-123 by Cellectis for Refractory Acute Myeloid Leukemia: Likelihood of Approval
UCART-123 is under clinical development by Cellectis and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...